Proxygen
Pre-clinicalProxygen hunts for molecular glue degraders because they solve the biggest challenge of drug discovery: disease-driving proteins that are difficult – or impossible – to drug.
Founded
2018
Focus
Small Molecules
About
Proxygen hunts for molecular glue degraders because they solve the biggest challenge of drug discovery: disease-driving proteins that are difficult – or impossible – to drug.
Funding History
2Total raised: $62M
Series A$50MNovartis Venture FundJan 15, 2022
Seed$12MBoehringer Ingelheim Venture FundJan 15, 2020
Company Info
TypePrivate
Founded2018
LocationVienna, Austria
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
AlgOss Biotechnologies
Pre-clinical · Graz
Angios Biotech
Pre-clinical ·
F4 Pharma
Pre-clinical · Vienna
aTENSION.life
Pre-clinical · Vienna
Austrianni
Pre-clinical · Vienna
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile